Trial Profile
A Randomized Study of Haploidentical Lymphocytes With Nivolumab and Intermediate Dose Cytarabine Versus Nivolumab and Intermediate Dose Cytarabine as Consolidation Treatment in Older Adults With Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Nivolumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Apr 2019 Status changed from recruiting to discontinued.
- 29 Dec 2017 New trial record